Dyslipidemia Drugs Global Market Analysis 2015 and Forecasts to 2023 Dyslipidemia Drugs Market - Global Industry Analys

Dyslipidemia Drugs Market - Global Industry Analysis, Size,
Share, Growth, Trends and Forecast 2015 – 2023
Dyslipidemia is a chronic metabolic syndrome, characterized by improper level of low density
lipoprotein, high density lipoprotein, and triglycerides. This study on the dyslipidemia drugs market
involves the analysis of a wide range of therapeutics that help patients to treat lipid disorders. The
dyslipidemia drugs market promises lucrative growth opportunities for pharmaceutical manufacturers
due to increasing demand and prescriptions of these medications. According to the Centers for
Disease Control and Prevention, cholesterol abnormalities are rapidly increasing in developed regions
such as North America and Europe. Moreover, several articles published in open journals stated that
demand for lipid lowering drugs is increasing in countries such as China, India, and Japan. However,
loss of patent exclusivity of molecules such as Crestor, Zetia, and Vytorin is expected to hamper the
growth of the market during the forecast period.
This 101 page report gives readers a comprehensive overview of the Dyslipidemia Drugs market Browse
through 27 data tables and 13 figures to unlock the hidden opportunities in this market.
http://www.transparencymarketresearch.com/dyslipidemia-market.html
This report comprises a detailed study of various drug classes for the treatment of dyslipidemia. The
dyslipidemia drugs market has been segmented into statins, bile acid resins, fibric acid derivatives,
niacins, and others (combination drugs and cholesterol absorption inhibitors). The statins segment
comprises combined market revenue of statin drugs such as atorvastatin, fluvastatin, rosuvastatin,
pravastatin, simvastatin, pitavastatin, and lovastatin. The bile acid resins segment included resins
such as Cholestyramine, Colestipol, Colesevelam, and Cholybar. The fibric acid, and omega-3 fatty
acid derivatives segment comprises generic drugs such as Fenofibrate, Clofibrate, and Bezafibrate.
Other branded omega-3 fatty acids include Lovaza, Vascespa, and Omtryg. Niacins includes drugs
such as Niaspan, Slo-Niacin, and Niacor. The others segment encompasses market analysis of
combination drug therapies such as Advicor, Vytorin, and Caduet, as well as cholesterol inhibitor
drugs. The market size and forecast for each drug class has been provided for the period from 2013
to 2023. The report also provides the compound annual growth rate (% CAGR) for the forecast period
from 2015 to 2023 for each drug class, considering 2013 to 2014 as the historical and base year,
respectively.
By geography, the dyslipidemia drugs market has been studied for five major regions: North America,
Europe, Asia Pacific, Latin America, and Middle East and Africa. Each region has been further divided
into major countries i.e., North America: the U.S. and Canada; Europe: Germany, France, the U.K.
and Rest of Europe; Asia Pacific: China, Japan, India and Rest of APAC; Latin America: Brazil and
Rest of LATAM; Middle East and Africa: South Africa and Rest of MEA. The market size and forecast
for each region and country has been estimated for the period 2013 to 2023 in terms of revenue (USD
million). The report also provides the compound annual growth rate (CAGR %) during the forecast
period from 2015 to 2023 for all the regions and countries mentioned above.